VLP vaccine promising against chikungunya
HONG KONG – The first human trial of a new vaccine based on virus-like particles (VLPs) suggests it is safe and effective against the rapidly emerging mosquito-borne chikungunya virus, researchers reported in the Aug. 15 early online edition of The Lancet.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter